{
    "eid": "2-s2.0-85074097306",
    "title": "Structural and In Vitro Functional Analyses of Novel Plant-Produced Anti-Human PD1 Antibody",
    "cover-date": "2019-12-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Multidisciplinary",
            "@code": "1000",
            "@abbrev": "MULT"
        }
    ],
    "keywords": [],
    "authors": [
        "Kaewta Rattanapisit",
        "Tanapati Phakham",
        "Supranee Buranapraditkun",
        "Konlavat Siriwattananon",
        "Chatikorn Boonkrai",
        "Trairak Pisitkun",
        "Nattiya Hirankarn",
        "Richard Strasser",
        "Yoshito Abe",
        "Waranyoo Phoolcharoen"
    ],
    "citedby-count": 28,
    "ref-count": 30,
    "ref-list": [
        "Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors",
        "Cancer Immunotherapies\u2013and Their Cost\u2013Take Center Stage at ASCO\u2019s 2015 Annual Meeting",
        "Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: Recent insights and future challenges",
        "Techno-economic analysis of a transient plant-based platform for monoclonal antibody production",
        "A simplified techno\u2010economic model for the molecular pharming of antibodies",
        "Predictive models for transient protein expression in tobacco (Nicotiana tabacum L.) can optimize process time, yield, and downstream costs",
        "The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza",
        "Plant-based production of biopharmaceuticals",
        "Regulatory approval and a first-in-human phase I clinical trial of a monoclonal antibody produced in transgenic tobacco plants",
        "Plant-derived pharmaceuticals\u2013the road forward",
        "Plant molecular pharming for the treatment of chronic and infectious diseases",
        "FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma",
        "Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial",
        "Rapid Transient Production of a Monoclonal Antibody Neutralizing the Porcine Epidemic Diarrhea Virus (PEDV) in Nicotiana benthamiana and Lactuca sativa",
        "A plant-produced vaccine protects mice against lethal West Nile virus infection without enhancing Zika or dengue virus infectivity",
        "High-level rapid production of full-size monoclonal antibodies in plants by a single-vector DNA replicon system",
        "Efficient In Vitro and In Vivo Activity of Glyco-Engineered Plant-Produced Rabies Monoclonal Antibodies E559 and 62-71-3",
        "In Vivo Glycan Engineering via the Mannosidase I Inhibitor (Kifunensine) Improves Efficacy of Rituximab Manufactured in Nicotiana benthamiana Plants",
        "Trastuzumab and Pertuzumab Plant Biosimilars: Modification of Asn297-linked Glycan of the mAbs Produced in a Plant with Fucosyltransferase and Xylosyltransferase Gene Knockouts",
        "Plant-derived anti-Lewis Y mAb exhibits biological activities for efficient immunotherapy against human cancer cells",
        "A KDEL-tagged monoclonal antibody is efficiently retained in the endoplasmic reticulum in leaves, but is both partially secreted and sorted to protein storage vacuoles in seeds",
        "Plant protein glycosylation",
        "Safety and immunogenicity of a plant-produced Pfs25 virus-like particle as a transmission blocking vaccine against malaria: A Phase 1 dose-escalation study in healthy adults",
        "Immunogenicity and safety of a quadrivalent plant-derived virus like particle influenza vaccine candidate-Two randomized Phase II clinical trials in 18 to 49 and >/=50 years old adults",
        "Human antibody response to N-glycans present on plant-made influenza virus-like particle (VLP) vaccines",
        "N-glycan engineering of a plant-produced anti-CD20-hIL-2 immunocytokine significantly enhances its effector functions",
        "Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy",
        "High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans",
        "Generation of glyco-engineered Nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human-like N-glycan structure",
        "FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Vienna",
            "@id": "60024895",
            "affilname": "Universitat fur Bodenkultur Wien",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60024895",
            "affiliation-country": "Austria"
        },
        {
            "affiliation-city": "Fukuoka",
            "@id": "60011047",
            "affilname": "Kyushu University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60011047",
            "affiliation-country": "Japan"
        }
    ],
    "funding": [
        "CUAASC",
        "Chulalongkorn Academic Advancement",
        "Ratchadaphiseksomphot Fund",
        "Chulalongkorn University",
        "National Science and Technology Development Agency"
    ]
}